# Lanzhou Biological

a subsidiary of China National Biotec Group (国药集团中国生物), the 30+ year national BoNT incumbent with 5,000+ medical institutions nationwide; 2025-2026 first-in-China indication expansions — primary axillary hyperhidrosis (NMPA approval November 25, 2025) and benign masseter hypertrophy (NMPA approval April 27, 2026,…

Source: https://en.bioecon.ru/companies/lanzhou-biological/
Updated: 2026-08-15

- Country: China

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Total assets reached $3.6 billion as of 2018 | https://dcvmn.org/member/cnbg/, https://www.ivi.int/the-cnbg-and-ivi-exchange-mou/ |
| Capacity | Annual human vaccine capacity up to 700 million doses; plasma collection capability of 1,400-1,500 tons annually | https://dcvmn.org/member/cnbg/, https://www.ivi.int/the-cnbg-and-ivi-exchange-mou/ |
| Certification | Product sold to 30+ countries; first Chinese company pre-qualified by the WHO for botulinum toxin | https://dcvmn.org/member/cnbg/, https://www.phirda.com/artilce_36441.html?module=trackingCodeGenerator |
| Regulatory approval | Botulinum toxin type A (Hengli) approved for various indications since 1997, with new indications (primary axillary hyperhidrosis, masticatory muscle hypertrophy) dated 2025-2026 | https://dcvmn.org/member/cnbg/, https://synapse.patsnap.com/drug/11fbeb521fc84d898bbbdc9110c873f3, https://synapse.zhihuiya.com/drug/11fbeb521fc84d898bbbdc9110c873f3 |
| Production site | 7 human vaccine manufacture sites, 2 animal vaccine manufacture sites, and 85 plasma collection stations nationwide | https://dcvmn.org/member/cnbg/, https://www.ivi.int/the-cnbg-and-ivi-exchange-mou/ |
| Headcount | Over 10,000 employees | https://dcvmn.org/member/cnbg/, https://www.ivi.int/the-cnbg-and-ivi-exchange-mou/ |
| Revenue | Total revenue reached $1.6 billion as of 2018 | https://dcvmn.org/member/cnbg/, https://www.ivi.int/the-cnbg-and-ivi-exchange-mou/ |

Independent sources: dcvmn.org, ivi.int, phirda.com, synapse.patsnap.com, synapse.zhihuiya.com

## Technologies

- [Recombinant botulinum toxin (biosynthetic Botox)](https://en.bioecon.ru/technology/recombinant-botulinum-toxin/)